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most expensive screening program in term of population ECs is TIR/TIR/ADN. How-
ever, this strategy has the lowest EC/neonate with CF. In the opposite TIR/ADN has
the lowest EC in term of population but the highest cost in term of neonates with
CF. However more data are needed in order to increase the power of estimations. It
is clear that the factors which have most influences in cost difference between
regions are algorithm type used, order of diagnostic tests and cutoff points.
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OBJECTIVES: Migraine is associated with significant medical costs in Western
countries. However, there is currently limited information comparing the eco-
nomic burden of different types of migraine including chronic migraine (CM) (15
headache days/month), especially in Asia. This study aims to estimate the medical
costs associated with chronic migraine in Taiwan. METHODS: A retrospective
matched cohort study was conducted utilizing data from the Taiwan National
Health Insurance Research Database. Cases of chronic migraine were defined as
patients with  one neurological outpatient visit with primary or secondary ICD-
9-CM code of 346.11, diagnosed by neurologists in medical centers during 2007-
2008. The 1st comparison group was other migraine sufferers (346.XX), without any
migraine diagnosis before 2007, matched with cases at a 4:1 ratio by age, gender,
and hospital setting. The 2nd comparison group was the general population with-
out any migraine diagnosis during 2005-2009, matched with cases at a 4:1 ratio by
age, gender, urbanization level of the residence and income. Medical costs within
365 days after the index date were assessed using a two-part model: a logistic
regression to predict the probability of use of services and a generalized linear
model to predict utilization for users of services. RESULTS:A total of 723 and 727 of
CM patients were matched with 2384 of other migraine sufferers and 2906 of the
general population, respectively. Patient with CM had significantly higher total
medical costs versus those with other migraine (NT$52527 vs. NT$41886,
differenceNT$10641; p0.001) or the general population (NT$61018 vs. NT$21377,
differenceNT$39641; p0.001). The mean drug costs for CM sufferers were higher
than those with other migraine (NT$16617 vs. NT$11217, differenceNT$5400;
p0.001) or the general population (NT$19691 vs. NT$7105, differenceNT$12586;
p0.001). CONCLUSIONS: Consistent with a higher burden of illness, CM sufferers
in Taiwan had significantly higher medical costs than those with other migraine
diagnoses or the general population.
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OBJECTIVES: The information on Sclerosis Multiplex (MS) health care and social
expenditures is not publicly available in Slovakia. The objective of the Cost of
Illness study was to establish the current cost of MS in order to provide a basis upon
which the economic impact of new treatments can be estimated. METHODS: The
analysis was performed based on the several data sources. Information on health-
care and social expenditure were obtained from State Health and Social Insurance
Funds. As not all detailed data on expenditures were available in a necessary struc-
ture, the missing data were collected in the patient research. Both direct and indi-
rect costs were evaluated and dissagregated by the cost type and severity of the
disease based on the EDSS score. Capital method is the most common method
applied for calculation of Indirect costs in MS and it was used in order to get
comparison with the data published in other countries. RESULTS: In Slovakia, the
prevalence of MS is 112/100 thousands inhabitans. Total yearly MS expenditures in
2010 were 40,7 mill. EUR. Direct costs counted for 57% of total costs and the most of
them (95%) were caused by drugs, hospitalisations and diagnostics (mostly MRI)
expenditures. The highest share of Indirect costs represented Loss of productivity
(58%), followed by Disability pensions (37%) and Sick leave wage compensation
(4%). Direct and indirect costs per one patient represent 3770 Eur and 2896 Eur
respectively.CONCLUSIONS:The evidence of cost-effectiveness of new treatments
must be demonstrated in order to get reimbursement in Slovakia. According the
Slovak Guidelines only direct costs are accepted in cost-effectiveness submissions
and indirect costs are taken into account only in reasonable cases. Indirect costs
represent nearly half of total MS costs (43%) and therefore should be considered in
assessing the cost effectiveness of new comming innovative MS therapies.
PND17
TREATMENT EXPERIENCE, BURDEN, AND UNMET NEEDS (TRIBUNE) IN
MULTIPLE SCLEROSIS STUDY: EXCESS BURDEN DUE TO RELAPSES
Karampampa K1, Gustavsson A1, Miltenburger C2, Eckert B3
1OptumInsight, Stockholm, Sweden, 2Former employee at OptumInsight, Stockholm, Sweden,
3Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: A Multiple Sclerosis (MS) relapse refers to an episode of neurological
disturbance during which an acute worsening of function occurs, usually lasting
for several days or weeks. The TRIBUNE study provides a detailed exploration of
costs and quality of life (QoL) associated with MS relapses. METHODS: Patients in
five European countries (France, Germany, Italy, Spain, and UK) completed a self-
administered web-based questionnaire capturing information on demographics,
disease characteristics and severity (EDSS), co-morbidities, relapses, resource con-
sumption, and relevant aspects of QoL. The effect of relapses on the socioeconomic
burden was assessed by the difference in costs and QoL incurred by relapsing-
remitting MS (RRMS) patients with and without relapse(s) with EDSS score 5.
RESULTS: Out of 1261 patients that completed the questionnaire, 68% had RRMS
and 87% reported receiving MS treatment. Nearly half (48%) of the RRMS patients
with an EDSS score  5 reported having at least one relapse during the past year.
This sub-group reported a higher consumption of direct medical resources, profes-
sional and informal care, and more sick-leave days compared to patients without
relapse(s). The difference in costs of patients with relapse(s) compared to those
without ranged between €3,321 and €9,430 across countries. Relapses requiring
treatment with steroids or hospitalization resulted in higher costs compared with
relapses not needing an intervention; €4,062 - €10,589 versus €340 - €5,096 respec-
tively across countries. QoL outcomes were also correlated with relapse(s).
CONCLUSIONS: The additional burden imposed by relapses is important both in
terms of excess cost and the impact on quality of life. The use of effective treat-
ments that reduce the frequency of relapses, in addition to providing clinical ben-
efits, could potentially lessen the clinical and socioeconomic burden of MS.
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OBJECTIVES: Muscular dystrophies (MD) are a group of genetically heterogeneous
disorders, characterized by progressive muscle wasting and weakness. The MDs
vary in incidence, pattern of inheritance, age of onset (though frequently among
pediatrics), muscles affected, and progression. Overall, MD imposes a significant
economic burden on both patients and society in general. This study assessed
recent trends in pediatric MD hospitalizations in the United States (US).METHODS:
Data for pediatric (20 years) hospitalizations with a primary diagnosis of MD
(ICD-9-CM codes 359.0, 359.1, or 359.2) from the 1997, 2000, 2003, and 2006 HCUP
Kids’ Inpatient Databases, nationally representative databases of pediatric hospi-
talizations in the US, were analyzed. Weighted estimates of the number of hospi-
talizations for MD, characteristics of these hospitalizations (e.g., patient demo-
graphics), and associated resource-based measures (i.e., charges, length of stay
[LOS], and most common primary procedures performed) were derived. RESULTS:
Between 1997 and 2006, the rate of pediatric MD-related hospitalizations (per
100,000 2010 US pediatric population) has increased, from 3.57/100,000 in 1997 to
4.12/100,000 in 2000, 4.39/100,000 in 2003, and 4.56/100,000 in 2006. Mean LOS de-
creased appreciably between 1997 and 2000, then remained unchanged through
2006 (10.7 days in 1997, and 9.4 days in 2000, 2003, and 2006). During each year of the
study period, continuous mechanical ventilation and dorsal and dorsolumbar fu-
sion (posterior technique) were the most frequently observed primary procedures.
Finally, mean total charges (2010 US $) for MD-related stays increased roughly 21%,
from $53,739 (1997) to $65,280 (2006). CONCLUSIONS: We examined rates of pedi-
atric MD-related hospitalizations in the US, and observed an increase in the rate of
hospitalizations over time. LOS decreased from 1997 to 2000, then remained con-
stant through 2006, although total charges increased significantly over this time.
These findings provide insight into MD-related hospitalizations in the US and high-
light the need to further examine the burden of MD.
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OBJECTIVES: Multiple sclerosis (MS) is a prevalent, chronic and disabling disease,
affecting mainly young adults. The most common clinical form presents with re-
current episodes of focal neurological deficits, called relapses. The aim of this work
is to analyse the socioeconomic cost of an MS relapse. METHODS: A prospective
observational study performed in 2 MS Units, located in Barcelona (Spain). We
included 100 consecutive patients (april 2007 to november 2009) who have had a
relapse. Patients were invited to answer a questionnaire after the relapse, with
demographic, social, employment status data and clinical aspects, as well as data
about the consumption of sanitary and no-sanitary resources during the relapse.
The unit costs were calculated according to the Catalan Health Service. RESULTS:
The mean age was 38.3 years, and 2 out of 3 were female sex. The mean duration of
disease was 9.5 years. 94% of patients had recurrent-remitting MS and secondary-
progressive 6%. At the time of the relapse 76% had a mild disability, 22% modeate
and 2% severe. 63% of patients reported to be employed. The relapse required a
mean of 3.1 medical visits, 3.7 days of outpatient hospitalization, 22.5 hours for
informal care and 12.4 sick leave days. The MS relapse costs resulted 2.609 euros
per patient. This included 1.524 euros of direct costs (medical visits: 183,7 euros,
complementary tests: 28,5 euros, hospitalizations days: 32,5 euros, outpatient hos-
pitalization:777,8 euros, displacements:152,9 euros, rehabilitation: 98,9 euros, in-
formale care: 151,7 euros, formal care: 21,5 euros and treatment: 76,5 euros) and
1.085 euros of indirect costs (sick leave days). CONCLUSIONS: Total cost of MS
relapse resulted (included direct and indirect costs) 2.609 euros per patient. The
main contributors to total cost were sick leaves and outpatient hospitalization.
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OBJECTIVES: To estimate the annual per patient cost of Amyotrophic Lateral Scle-
rosis (ALS) in Greece from a societal point of view. METHODS: Data on direct costs
(medications, laboratory/imaging tests, consultations, hospitalizations) were ob-
tained through retrospective chart review of a sample of patients followed-up in
Aeginition University Hospital, a reference centre for ALS in Greece. Eligible pa-
tients were those that visited the ALS clinic in the previous 6 months and had fully
recorded data for the previous year. Patients were also personally interviewed,
following consent, based on a strictly-structured questionnaire, with an aim to
record indirect costs incurred in the previous year (work absenteeism, professional
home help, walking aids). Unit prices for health-resource use were the official NHS
prices. Work loss and home help were costed with the hourly rate of the basic
salary, in order to obtain a conservative approach. Costs are reported in year 2011
Euros. RESULTS: The sample (N34) was 53% female with an average age of 61.6
years. Total average annual per patient cost was 7450.6€ (standard deviation:
6423€), out of which 4136.3€ (s.d. 1,350€) were direct and 3314.2€ (s.d. 6190€) were
indirect expenditure. Medications accounted for 32.7% of the total cost, followed by
professional home help (24.4%), work absenteeism (17.7%) and hospitalizations
(9.2%). Women had a significantly higher average cost than men (10,004€ vs. 4,347€,
p0.05), mostly as a result of indirect expenditures from productivity loss. Age65
did not have a significant impact on outcomes due to the substitution of produc-
tivity losses (65) by home help, for patients 65. CONCLUSIONS: ALS entails a
significant per patient economic burden in societal terms. Cost-of-illness data,
even for rare diseases, provide important inputs for the decision-making process in
health as well as for awareness purposes.
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OBJECTIVES: Alzheimer’s disease (AD) is the most common form of dementia.
Estimates of the cost of AD in Romania come from external sources and are based
on extrapolations and assumptions. We tried to replace some of the assumptions
with actual data obtained from official sources and based on data obtained from
the Bucharest Memory Center. METHODS: This is an empirical investigation of the
economic cost of AD in Romania in 2010. Direct and indirect costs are estimated
and allocated to the AD by taking in consideration an extrapolation of European
data for incidence and prevalence, actual cost for medication provided by National
Insurance House for specific medication used in prevention an treatment of AD,
actual data provided by Ministry of Labor and Social Security for persons with AD
living in nursing home. Cost of care provided by family members were estimated
on a telephonic cross-sectional survey, carried out using the database of Bucharest
Memory Center. RESULTS: The calculated cost of Alzheimer’s disease in Romania
is 187.022.387 €, direct medical cost of 62 millions €, 7.5 million € for hospitalization,
medication of 34.9 million €, ambulatory medical services of 0.4 million €, nursing
home costs of 4.6 million €, parapharmaceuticals cost of 15 million € and indirect
(informal) cost of 124.5 million €. CONCLUSIONS: There is a major discrepancy
between the cost obtained by Wimo A. et al in 2010 and ours, which is 10 times
smaller. The main difference is due the small number of people hospitalized in
specialized centers, only 3%, the small number of people receiving treatment - only
14% of the total number of patients with DA. Romania must strive to remove the
inequities concerning informal costs and be prepared for an exponentially increase
of costs as the care of patients will normalize.
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OBJECTIVES: To estimate the annual per patient cost of Myasthenia Gravis (MG) in
Greece from a societal perspective. METHODS: Data on direct costs (medications,
laboratory/imaging tests, consultations, hospitalizations) were obtained through
retrospective chart review of a sample of patients followed-up in Aeginition Uni-
versity Hospital, a reference centre for MG in Greece. Eligible patients were those
that visited the MG clinic in the previous 6 months and had fully recorded data for
the previous year. Patients were also personally interviewed, following consent,
based on a strictly-structured questionnaire, with an aim to record indirect costs
incurred in the previous year (premature retirement, work absenteeism, decreased
productivity, professional home help). Unit prices for health-resource use were the
official NHS prices. Productivity losses and home help were costed with the hourly
rate of the basic salary, in order to obtain a conservative approach. Costs are re-
ported in year 2011 Euros. RESULTS: The sample (N32) was 56% female with an
average age of 57 years (men: 66.6, women: 49.5). Average total annual per patient
cost was 4125.4€ (standard deviation: 5287€), out of which 614.3€ (s.d.: 496€) were
direct and 3511.5€ (s.d.: 5260.5€) were indirect expenditure. Early retirement, home
help, and medications were the major cost drivers of total cost (49%, 31% and 8%
respectively), while medications had the biggest influence when focusing on direct
costs alone (51%). Women had a higher average cost than men (5173€ vs. 2777€),
principally as a result of indirect expenditures from lost productivity.
CONCLUSIONS: MG is a burdensome disease, in socioeconomic terms, that seems
to affect women more heavily, compared to men, most probably due to symptom
onset at a younger (and more productive) age. Even in the case of low prevalence-
or rare-diseases, cost-of-illness analysis can promote awareness and contribute
with the necessary data to health policy decisions.
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OBJECTIVES: Multiple sclerosis (MS) is a prevalent, chronic and disabling disease,
mainly affecting young adults. The aim of the present work is to analyse the cost of
the informal care of MS according to disability, in different Spanish regions.
METHODS: Patients with clinical diagnosis of MS, from different Spanish regions,
were selected between december 2006 and december 2010. The patients were di-
vided in 3 groups based on their disability: mild (EDSS 0-3,5), moderate (EDSS 4,0-
6,5) and severe (7,0-9,5). They were invited to answer a questionnaire, with demo-
graphic, social, employment status data, clinical aspects, as well as data about the
consumption of sanitary and no-sanitary resources during the MS process. The
replacement method was used to estimate informal costs. RESULTS: We analized
1107 pacients and 317 caregivers. The percentage of patients requiering informal
care increased with disability, ranging from 7% (mild disability) to 73% (severe
disability) and daily hours of informal care per patient, 0.4 (mild disability) to 11.8
(severe disability). These informal cares can also vary depending on the Spanish
region analyzed. The caregiver mean age was 53 years, is mostly the patient’s
partner (54%) and has been practicing as a caregiver a mean of 10 years. The esti-
mated cost of informal care increased with disability, ranging from 777 euros/
patient/year (mild disability) to 26.987 euros/patient/year (severe disability). The
cost grew to 45% of the total cost of the disease in advanced stages. CONCLUSIONS:
The estimated cost of informal care increased with disability, ranging from 777
euros/patient/year (mild disability) to 26,987 euros/patient/year (severe disability).
It represented almost half of the total cost of the disease in advanced stages.
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OBJECTIVES: Drug therapy in Multiple Sclerosis (MS) accounts for a significant
proportion of the economic burden of this disease. Expenditure on disease-modi-
fying-therapies (DMT) in Ireland was €32.7 million in 2009, 1.63% of total pharma-
ceutical expenditure. In addition to DMT, other non-DMT drugs are used to treat MS
symptoms. This study describes the patterns and cost of non-DMT (other) drug
utilisation in Ireland.METHODS:A cohort of patients dispensed a DMT during 2009
were identified from a national prescribing database. An analysis of all other drugs
dispensed for this cohort during 2009 was undertaken. RESULTS: A cohort of 2749
people on DMT was identified (39.3% of the estimated Irish MS population) 69.0% of
whom also received other drugs costing €2.7 million (estimated 7.6% of total MS
drug costs). The mean other drug cost per person on DMT was €1417 (SD €1863).
Drug classes contributing most to other drug costs were antiepileptics (17.1%) used
for neuropathic pain, urinary antispasmodics (8.1%) and muscle relaxants (7.0%).
The top 10 drugs by cost included pregabalin, gabapentin, modafinil, tizandine,
tolterodine, evening primrose oil, atorvastatin, venlafaxine, baclofen and escitalo-
pram (39.9% of other drug costs). The most commonly prescribed drug classes –
antidepressants, analgesics and NSAIDs, dispensed to over 20% of the cohort in
each case, accounted for just 12.7% of other drug costs. CONCLUSIONS: Character-
isation of non-DMT drug use provides useful information for clinicians, healthcare
payers, and those undertaking cost-of-illness studies. While these drugs account
for a smaller proportion of overall costs than DMT, they are an indication of overall
morbidity and wider resource utilisation e.g. urological drugs as an indicator for
physiotherapy and incontinence equipment. These results can be considered in
the design of future cost-of-illness surveys which often include an exhaustive list
of individual drugs.
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OBJECTIVES: Population characteristics of patients with epilepsy remain poorly
documented in France. Reimbursement databases may be useful to perform cost
and epidemiological studies provided that patient diagnoses can be identified ei-
ther directly, or indirectly through the use of antiepileptic drugs (AEDs) as markers.
This study explored the possibility to use the French reimbursement database to
determine the prevalence and direct cost of epilepsy. METHODS: The “EGB” reim-
bursement database is a 1/97 representative sample (500,000 individuals) of the
population covered under the French General Scheme. Only a fraction of patients
fully covered for epilepsy can be identified on a diagnosis basis. The rest of them
can only be identified through their treatment by AEDs, but some are not specific to
epilepsy (e.g. benzodiazepines). An algorithm was built to identify patients with
epilepsy and calculate an estimation of the prevalence. In parallel, total medical
expenses of patients were derived on the fully covered sub-population. RESULTS:
Only patients treated with polytherapy (2 AEDs) could be identified in a relevant
way by an algorithm based on drug use. The prevalence of epilepsy in this sub-
group in 2009 was estimated between 1.83‰ and 2.79‰ (93,000 – 142,000 patients).
A proportion of 70.1% to 71.6% were fully covered by insurance for their expenses,
with epilepsy alone as a cause in only 27 to 33% of them. The most frequent
comorbidities were psychiatric disorders and incapacitating stroke. The annual per
capita expenses were in the range of 6601€- 6696€ for patients with polytherapy,
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